Shares in Swedish microcap Nanexa more than doubled after the drug‑delivery group announced a licensing deal with European pharmaceutical giant Novo Nordisk.
The agreement gives Novo Nordisk access to Nanexa’s proprietary drug‑delivery technology, which could be used to develop new injectable products.
Nuevo Nordisk is a leading European pharma company, best known for its obesity drug Wegovy, and the partnership is seen as a significant boost for Nanexa’s commercial prospects.
Following the announcement, Nanexa’s stock surged, reflecting investor confidence in the potential revenue streams and the expansion of its product pipeline.
As a small‑cap company, the deal could markedly increase Nanexa’s valuation and position it for further growth in the competitive drug‑delivery market.
<small>Source: CNBC — read the original story there.</small>